These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12540801)

  • 21. Somatostatin analogs and hepatocellular carcinoma: Not dead yet?
    Raftery L; O'Neil BH
    Cancer Biol Ther; 2009 Nov; 8(21):2040-1. PubMed ID: 19823044
    [No Abstract]   [Full Text] [Related]  

  • 22. Chemotherapy and medical treatment of hepatocellular carcinoma (HCC).
    Rougier P; Mitry E; Clavero-Fabri MC
    Hepatogastroenterology; 1998 Aug; 45 Suppl 3():1264-6. PubMed ID: 9730386
    [No Abstract]   [Full Text] [Related]  

  • 23. Systemic treatment of hepatocellular carcinoma.
    Treiber G
    Dig Dis; 2001; 19(4):311-23. PubMed ID: 11935091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage.
    Plentz RR; Tillmann HL; Kubicka S; Bleck JS; Gebel M; Manns MP; Rudolph KL
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1422-8. PubMed ID: 16105131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment outcomes with long acting octreotide in inoperable hepatocellular carcinoma: a local experience and review of literature.
    Gill ML; Atiq M; Sattar S; Khokhar N
    J Pak Med Assoc; 2005 Apr; 55(4):135-8. PubMed ID: 15918622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment with inhibitors of angiogenesis in advanced hepatocellular carcinoma: a new tool in our hands or simply a hope?
    Cipriani G; Mazzanti R
    Dig Liver Dis; 2005 Apr; 37(4):230-1. PubMed ID: 15788205
    [No Abstract]   [Full Text] [Related]  

  • 27. Re: Liu et al.--Estrogen receptor status in inoperable hepatocellular carcinoma.
    Chow PK; Hung H; Soo KC
    Am J Gastroenterol; 2001 Apr; 96(4):1297-8. PubMed ID: 11316190
    [No Abstract]   [Full Text] [Related]  

  • 28. Local/regional and systemic treatments of hepatocellular carcinoma.
    Beaugrand M; N'kontchou G; Seror O; Ganne N; Trinchet JC
    Semin Liver Dis; 2005; 25(2):201-11. PubMed ID: 15918148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Octreotide in control of multiple liver metastases from gastrinoma.
    Saijo F; Naito H; Funayama Y; Fukushima K; Shibata C; Hashimoto A; Kitayama T; Nagao M; Matsuno S; Sasaki I
    J Gastroenterol; 2003; 38(9):905-8. PubMed ID: 14564638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma.
    Attia S; Holen KD; Thomas JP; Richie K; Dzelak T; Teeter K; Warren D; Bilger A; Fine J; Eickhoff J; Drinkwater N; Mulkerin D; Morgan-Meadows S
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):44-54. PubMed ID: 18322441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial.
    Pan DY; Qiao JG; Chen JW; Huo YC; Zhou YK; Shi HA
    Hepatobiliary Pancreat Dis Int; 2003 May; 2(2):211-5. PubMed ID: 14599971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Octreotide therapy for hepatocellular carcinoma: a systematic review of the evidence from randomized controlled trials.
    Jia WD; Zhang CH; Xu GL; Ge YS; Wang W
    Hepatogastroenterology; 2010; 57(98):292-9. PubMed ID: 20583430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Octreotide therapy for advanced hepatocellular carcinoma.
    Slijkhuis WA; Stadheim L; Hassoun ZM; Nzeako UC; Kremers WK; Talwalkar JA; Gores GJ
    J Clin Gastroenterol; 2005 Apr; 39(4):333-8. PubMed ID: 15758629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A dramatic response to long-acting octreotide in metastatic hepatocellular carcinoma.
    Deming DA; Stella AL; Holen KD; Ku G; O'Reilly EM
    Clin Adv Hematol Oncol; 2005 Jun; 3(6):468-72; discussion 472-4. PubMed ID: 16167024
    [No Abstract]   [Full Text] [Related]  

  • 35. Tamoxifen in hepatocellular carcinoma.
    Chow P; Kiat TC; Choo TB; Machin D
    Lancet; 1998 Sep; 352(9130):819-20. PubMed ID: 9737316
    [No Abstract]   [Full Text] [Related]  

  • 36. Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors.
    Notas G; Kolios G; Mastrodimou N; Kampa M; Vasilaki A; Xidakis C; Castanas E; Thermos K; Kouroumalis E
    J Hepatol; 2004 May; 40(5):792-8. PubMed ID: 15094227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regression of a hepatocellular carcinoma following treatment with octreotide and tamoxifen in a patient with advanced alcoholic cirrhosis.
    Senturk H; Canbakan B; Cumali R
    J Gastroenterol Hepatol; 2004 Jun; 19(6):719-20. PubMed ID: 15151636
    [No Abstract]   [Full Text] [Related]  

  • 38. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.
    Butturini G; Bettini R; Missiaglia E; Mantovani W; Dalai I; Capelli P; Ferdeghini M; Pederzoli P; Scarpa A; Falconi M
    Endocr Relat Cancer; 2006 Dec; 13(4):1213-21. PubMed ID: 17158766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Well-differentiated endocrine carcinoma of the renal pelvis: report of a case with sustained objective response to octreotide.
    Walter T; Mege-Lechevallier F; Scoazec JY; Martin X; Chayvialle JA; Lombard-Bohas C
    Pathol Res Pract; 2009; 205(3):183-7. PubMed ID: 19041194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials.
    Guo TK; Hao XY; Ma B; Yang KH; Li YP; Li HL; Gu YH; Cai H; Liu YL; Li Y; Zhan WP
    J Cancer Res Clin Oncol; 2009 Dec; 135(12):1685-92. PubMed ID: 19536563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.